Progress in efficacy and safety of vigabatrin in treatment of epilepsy associated with tuberous sclerosis complex in children
10.3760/cma.j.issn.1673-4408.2023.05.003
- VernacularTitle:氨己烯酸治疗儿童结节性硬化症相关癫痫的疗效及安全性研究进展
- Author:
Siqi ZHU
1
;
Jiwen WANG
Author Information
1. 上海交通大学医学院附属上海儿童医学中心神经内科 200127
- Keywords:
Vigabatrin;
Tuberous sclerosis complex;
Epilepsy;
Infantile spasms
- From:
International Journal of Pediatrics
2023;50(5):302-305
- CountryChina
- Language:Chinese
-
Abstract:
Tuberous sclerosis complex(TSC)is an autosomal dominant skin-nerve syndrome with diverse clinical manifestations.Epilepsy is the most common neurological manifestation.Vigabatrin(VGB)is an inhibitory neurotransmitter γ-aminobutyric acid(GABA)analogue.It reduces the degradation of GABA by irreversibly binding to GABA transaminase, thereby increasing the level of GABA in the central nervous system and exerting anti-epileptic effects.It is suitable for the treatment of various types of epilepsy related to TSC.In recent years, the preventive effect of VGB in TSC-related epilepsy has attracted wide attention.There is a certain degree of adverse reactions during the use of VGB, the most noteworthy of which is the visual field and central nervous system changes.This article reviews the efficacy and safety of VGB in the treatment of TSC-related epilepsy.
